Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Non-Current Deferred Tax Liability (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with $425527.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 49.52% to $425527.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $425527.0 through Dec 2025, down 49.52% year-over-year, with the annual reading at $495113.0 for FY2025, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $425527.0 at Neuphoria Therapeutics, down from $460320.0 in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $1.3 million in Q2 2022, with the low at $425527.0 in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 4 years is $776452.9, with a median of $796530.5 recorded in 2024.
  • The sharpest move saw Non-Current Deferred Tax Liability dropped 14.12% in 2023, then crashed 49.52% in 2025.
  • Over 4 years, Non-Current Deferred Tax Liability stood at $1.3 million in 2022, then dropped by 14.12% to $1.1 million in 2023, then decreased by 23.81% to $842921.0 in 2024, then plummeted by 49.52% to $425527.0 in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $425527.0, $460320.0, and $495113.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.